Psoriasis Biologicals Market Size, Growth | Global Report 2023

According to Precision Business Insights (PBI), the global psoriasis biologicals market size was valued at USD 24,874.9 billion in 2021 and is poised to grow at a significant CAGR of 9.8% during the forecast period 2022 to 2028. The global psoriasis biologicals market is segmented into the following types: by Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies), Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, and Other Mechanisms of Action), Route of Administration (Oral, Parenteral, and Topical)and Geography (North America, Europe, Asia Pacific, Latin America, and MEA) and Forecast to 2028. Key players' profiles in the Psoriasis Biologicals market report are AbbVie Inc, Amgen Inc., AstraZeneca, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Dr.Reddy`s Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnson (Janssen Biotech Inc.), Leo Pharma AS. The rapidly growing geriatric population, rising prevalence of plaque and psoriatic arthritis, a large pipeline of biologic and biosimilar products, favourable reimbursement policies, and rising biologic product prescription volume are all major factors driving the growth of the global psoriasis biologicals market.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/psoriasis-biologicals-market/

Interleukin Inhibitors Segment to Dominate the Psoriasis Biologicals Market
Amongst Mechanisms of Action, the Interleukin Inhibitors segment held a considerable market during the estimated period. Interleukin inhibitors benefit from greater safety and efficacy when compared to other groups of psoriasis medications, which typically leads to increasing patient acceptance. Taltz (Ixekizumab), Cosentyx (Secukinumab), Siliq (Brodalumab), Tremfya (Guselkumab), Ilumya (Tildrakizumab), and SKYRIZI (Risankizumab) are examples of major licenced interleukin antibodies. Drug approvals by regulatory bodies are also contributing to the segment's growth. For example, in January 2022, AbbVie gained FDA clearance for SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for the treatment of individuals with active psoriatic arthritis (PsA). This systemic inflammatory disease, which affects the skin and joints, affects around 30% of psoriasis sufferers. Such approvals and launches are contributing to the growth of the market segment. Thus, owing to the abovementioned factors, the market segment is expected to show significant growth over the forecast period.

Asia Pacific Psoriasis Biologicals Market
The global psoriasis biologicals market, based on region, is segmented into America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is anticipated to grow due to a growth in disease burden and demand for psoriasis medications, rising usage of combination therapy, and an explosion in psoriasis research and pipeline pharmaceuticals. Because of the high incidence of psoriasis in North America, the United States has the biggest market share.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players.

The global Psoriasis Biologicals market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance,

In July 2022. The United States Food and Drug Administration (FDA) approved Arcutis Biotherapeutics, Inc.'s New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous regions, in patients 12 years of age and older.

Request sample report at- https://precisionbusinessinsights.com/request-sample/?product_id=65351

Detailed Segmentation
The Psoriasis Biologicals market is segmented based on By Type of Treatment, By Mechanism of Action, By Route of Administration, and geography.

Based on the Type of Treatment, the market is segmented into the following:
• Biologic Drugs
• Small Molecule Systemic Drugs
• Tropical Therapies

Based on the Mechanism of Action, the market is segmented into the following:
• TNF Alpha Inhibitors
• PDE4 Inhibitors
• Interleukin Inhibitors
• Other Mechanisms of Action

Based on the Route of Administration, the market is segmented into the following:
• Oral
• Parenteral
• Topical

Based on geography, the market is segmented into the following:

• North America
o USA
o Canada
• Europe
o Germany
o UK
o France
o Spain
o Italy
o Russia
o Rest of Europe
• The Asia Pacific
o China
o India
o Japan
o ASEAN
o Australia & New Zealand
o Rest of Asia-Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• MEA
o Gulf Cooperation Council (GCC) Countries
o Israel
o South Africa
o Rest of MEA

Request methodology for https://precisionbusinessinsights.com/request-methodology/?product_id=65351

There are several industry players working in the Psoriasis Biologicals Market, which include AbbVie Inc., Amgen Inc., AstraZenca, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Reddy`s Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnson (Janssen Biotech Inc.), Leo Pharma AS.

Contact:
Mr. Satya
Precision Business Insights| Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.